

WCHN Clinical Research Active Trials

Cancer Type	Trial Name	Sponsor	Site	Norwalk IRB #
Breast	CLEE011E2301: A randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI: letrozole or anastrozole) and goserelin for the treatment of premenopausal women with hormone receptor (HR)-positive, HER2-negative, advanced breast cancer	NOVARTIS	D	n/a
	Z11102 – Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)	ACOSOG	D	
	A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3N1) Who Have Positive sentinel Lymph Node Disease after Neoadjuvant Chemotherapy	Alliance	N	15-02
	M12-914: A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable <i>BRCA</i> -Associated Breast Cancer	Abbvie	N	15-01
	WO29522: A Phase III, Multicenter, Randomized, Placebo-Controlled Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination With NAB-Paclitaxel For Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer	Roche	N	15-11
Colon	N1048: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision	Alliance	N	12-14
Kidney	S0931: EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study	SWOG	D	n/a

Lung -Squamous Cell	<p>S1400 - Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer</p> <p>S1400B: A Phase II/III Randomized Study of GDC-0032 Versus Chemotherapy as Second Line Therapy for Biomarker Selected Patients with Squamous Cell Lung Cancer</p> <p>S1400C: A Phase II/III Randomized Study of Palbociclib Versus Chemotherapy as Second Line Therapy for Biomarker Selected Patients with Squamous Cell Lung Cancer</p> <p>S1400D: A Phase II/III Randomized Study of AZD4547 Versus Chemotherapy as Second Line Therapy for Biomarker Selected Patients with Squamous Cell Lung Cancer</p> <p>S1400I: A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients w/Stage IV Squamous Cell Lung Cancer and no Matching Biomarker (Lung-Map Sub Study)</p>	SWOG	D	n/a
Lung -NSCLC	<p>RES-RSP-12-006: Decision Impact Analysis of Foundation Medicine's Next Generation Sequencing Test in Advanced Non-Small Cell Lung Cancer</p>	Foundation Medicine	N	12-09
	<p>ALCHEMIST: A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial</p>	Alliance	D	n/a
	<p>A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer</p>	Alliance	D	n/a
	<p>E4512: A Phase III Double Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein</p>	ECOG-ACRIN	D	n/a
	<p>GO29437: A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of MPDL3280A (anti-PD-L-1 antibody) in Combination with Carboplatin + Paclitaxel or MPDL3280A in Combination with Carboplatin + Nab-Paclitaxel, versus Carboplatin + Paclitaxel in chemotherapy naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)</p>	Roche	D	n/a
	<p>GO29436: Phase III, Open-Label, Randomized Study of MPDL3280A (anti-PD-L-1 antibody) in Combination with Carboplatin + Paclitaxel with or without Bevacizumab compared with Carboplatin + Paclitaxel + Bevacizumab in chemotherapy naïve patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer</p>	Roche	D	n/a
	<p>GO29527: A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A Compared with Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in PD-L1-SELECTED Patients with Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer</p>	Roche	D	n/a

Lymphoma	CC-5013-NHL-008: A phase 3b randomized study of lenalidomide (CC-5013) plus rituximab maintenance therapy followed by lenalidomide single-agent maintenance versus rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma	Celgene	N	14-07
	PCI-32765CAN3001: A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study	Janssen	N	15-04
	GS-US-339-0102: A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies	Gilead	N	15-07
Ovarian	GOG 0225: Can Diet And Exercise Modulate Ovarian, Fallopian Tube And Primary Peritoneal Cancer Progression-Free Survival?	GOG	D	n/a
Multiple Myeloma	54767414MMY3008: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy	Janssen	N	15-15
	RareCyte Technology: Detection and Enumeration of Circulating Plasma Cells in Patients with MGUS and Myeloma using RareCyte Technology	Dr. Fiedler	D	n/a
	E3A06 – Randomized phase III trial of Lenalidomide versus Observation Alone in Patients with Asymptomatic High Risk Smoldering Multiple Myeloma	ECOG-ACRIN	D	
Pancreatic	IMMU-107-04: An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of ⁹⁰ Y-Clivatuzumab Tetraxetan plus Low-Dose Gemcitabine Versus Placebo plus Low-Dose Gemcitabine in Patients with Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)	Immunomedics	N	14-09
	PCYC-1137-CA – Randomized, Multicenter, Double-Blinded, Placebo-controlled, Phase 2/3 study of Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination with Nab-Paclitaxel and Gemcitabine vs. Placebo in Combination with Nab-Paclitaxel and Gemcitabine, in First Line Treatment of Patients with Metastatic Pancreatic Adenocarcinoma		D	
	The Role of MicroRNAs in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer	Richard Frank Cristiano Ferlini	N/D	15-10
	The Use of Endoscopic Ultrasound with Fine Needle Biopsy in the Molecular Analysis of Pancreatic Cancer	Frank, Merchant, Brandwine, Gorelick, Mangla, Anand, Ferlini	N/D	15-16

Prostate	A031201: Phase III trial of enzalutamide (NSC # 766085) versus enzalutamide, abiraterone and prednisone for castration resistant metastatic prostate cancer	Alliance	N	14-05
Phase 1	AMG 232 20120106: A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 (p53 inhibitor) in Adult Subjects with Advanced Solid Tumors or Multiple Myeloma**separate cohorts for glioblastoma, breast,liposarcoma	Amgen	N	13-01
	EMR 100070-001: A Phase I , Open-Label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C (anti-PD-L1) in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to selected Indications	EMD Serono	N	14-02
Signature (P2P)	CBGJ398XUS04: Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors with FGFR Genetic Alterations	Novartis	N	Quorum
Diagnostic: Multiple sites	The National Oncologic Pet Registry : NaFlouride PET (bone mets)		D	n/a
	PI-13-1008: Characterization of Human Cancers by Molecular Profiling of Patient Biospecimen	Pharmatech	N	Compass

D = open at Danbury and New Milford Hospitals / N = open at Norwalk Hospital

Updated 12/18/2015